The outcomes are in and they add to the evidence of why the industry needs to reconsider its approach because how can any process lacking clear ministerial direction and administered by antagonistic officials possibly end well?
Final outcomes add to the evidence of the need for a new approach
December 8, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 19 June
June 19, 2026 - - Podcast -
Gilead rushes remdesivir to Uganda to support Ebola response
June 19, 2026 - - Latest News -
Infectious diseases across the lifespan are a hidden burden beyond the acute episode
June 19, 2026 - - Latest News -
Sanofi volunteers confront homelessness at Vinnies CEO Sleepout
June 19, 2026 - - Latest News -
Rhapsido approved in Australia as first oral targeted option for chronic spontaneous urticaria
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News

